title: Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
abstract: The choice of inhaler device for bronchodilator reversibility is crucial since suboptimal inhalation technique may influence the result. On the other hand, bronchodilator response also varies from time to time and may depend on patient characteristics. In this study, patients with airway obstruction (forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] ratio <70% in chronic obstructive pulmonary disease [COPD]; <80% in asthma) were included (n=121, age: 57.8±17.3 years). Bronchodilator reversibility (American Thoracic Society/European Respiratory Society criteria) was tested in patients with COPD (n=63) and asthma and COPD overlap syndrome (ACOS; n=12). Forty-six asthmatics served as controls. Reversibility was tested with 400 µg salbutamol dry powder inhaler (Buventol Easyhaler, Orion Pharma Ltd, Espoo, Finland). Demographic data and patients' perceptions of Easyhaler compared with β2-agonist pressurized metered dose inhalers (pMDIs) were analyzed. American Thoracic Society/European Respiratory Society guideline defined reversibility was found in 21 out of 63 COPD patients and in two out of 12 ACOS patients. Airway obstruction was more severe in COPD patients as compared with controls (mean FEV1 and FEV1% predicted both P<0.0001). Average response to salbutamol was significantly lower in COPD patients compared with asthma controls (P<0.0001). Reversibility was equally often found in smokers as in never-smokers (33% vs 34%). Nonreversible COPD patients had higher mean weight, body mass index, and FEV1/FVC compared with reversible COPD patients. Most patients preferred Easyhaler and defined its use as simpler and more effective than use of a pMDI. Never-smokers and patients with asthma experienced Easy-haler somewhat easier to use than smokers and patients with COPD. In conclusion, a substantial part of patients with COPD or ACOS showed reversibility to salbutamol dry powder inhaler. Nonreversible patients with COPD were characterized by higher weight and body mass index, and a higher FEV1/FVC ratio. Most patients preferred Easyhaler compared with a pMDI.
authors.affiliation: Department of Pulmonology, Semmelweis University, Budapest, Hungary.
authors.forename: Veronika
authors.initials: V
authors.lastname: Müller
authors.affiliation: Department of Pulmonology, Semmelweis University, Budapest, Hungary.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Gálffy
authors.affiliation: Department of Pulmonology, Semmelweis University, Budapest, Hungary.
authors.forename: Márta
authors.initials: M
authors.lastname: Orosz
authors.affiliation: Department of Pulmonology, Semmelweis University, Budapest, Hungary.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Kováts
authors.affiliation: Department of Pulmonology, Semmelweis University, Budapest, Hungary.
authors.forename: Balázs
authors.initials: B
authors.lastname: Odler
authors.affiliation: Semeco AB, Ängelholm, Sweden.
authors.forename: Olof
authors.initials: O
authors.lastname: Selroos
authors.affiliation: Department of Pulmonology, Semmelweis University, Budapest, Hungary.
authors.forename: Lilla
authors.initials: L
authors.lastname: Tamási
mesh_terms: D000280:Administration, Inhalation; D000368:Aged; D000402:Airway Obstruction / Q000188:drug therapy / Q000523:psychology; D000420:Albuterol / Q000008:administration & dosage*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D058995:Dry Powder Inhalers / Q000706:statistics & numerical data*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D008297:Male; D036501:Metered Dose Inhalers / Q000706:statistics & numerical data*; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D057240:Patient Preference; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D012129:Respiratory Function Tests / Q000379:methods
chemical_list: D001993:Bronchodilator Agents; D000420:Albuterol
keywords: ACOS; COPD; Easyhaler; asthma; bronchodilator reversibility; salbutamol
references.citation: J Allergy Clin Immunol. 2013 Mar;131(3):627-34; quiz 635
references.pmid: 23360757
references.citation: Expert Rev Clin Pharmacol. 2013 Mar;6(2):197-219
references.pmid: 23473596
references.citation: Drugs R D. 2013 Sep;13(3):215-22
references.pmid: 24043456
references.citation: Clin Respir J. 2013 Oct;7(4):342-6
references.pmid: 23362945
references.citation: Expert Opin Drug Deliv. 2014 Jan;11(1):1-3
references.pmid: 24093806
references.citation: Lancet Respir Med. 2013 Sep;1(7):564-73
references.pmid: 24461617
references.citation: Clin Chest Med. 2014 Mar;35(1):143-56
references.pmid: 24507842
references.citation: Respiration. 2014;88(1):3-15
references.pmid: 24902629
references.citation: Curr Allergy Asthma Rep. 2015 Mar;15(3):509
references.pmid: 25712010
references.citation: Int J Chron Obstruct Pulmon Dis. 2015;10:947-54
references.pmid: 26028967
references.citation: Eur Respir J. 1999 Jan;13(1):197-205
references.pmid: 10836348
references.citation: J Aerosol Med. 2001 Summer;14(2):217-25
references.pmid: 11681653
references.citation: Health Technol Assess. 2001;5(26):1-149
references.pmid: 11701099
references.citation: Arch Bronconeumol. 2004 Mar;40(3):106-9
references.pmid: 14998473
references.citation: Eur Respir J. 2004 Jun;23(6):932-46
references.pmid: 15219010
references.citation: Chest. 2004 Aug;126(2):375-81
references.pmid: 15302720
references.citation: Ann Intern Med. 1983 Nov;99(5):612-20
references.pmid: 6357018
references.citation: Arch Intern Med. 1988 Sep;148(9):1949-52
references.pmid: 3046537
references.citation: Thorax. 1992 Jun;47(6):429-36
references.pmid: 1496502
references.citation: Ann Allergy. 1994 Feb;72(2):178-82
references.pmid: 8109809
references.citation: Respiration. 1994;61(1):37-41
references.pmid: 8177971
references.citation: Arzneimittelforschung. 1995 Jan;45(1):44-7
references.pmid: 7893268
references.citation: Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36
references.pmid: 7663792
references.citation: Chest. 2005 Jan;127(1):335-71
references.pmid: 15654001
references.citation: Int J Clin Pract. 2005 Apr;59(4):385-98
references.pmid: 15853852
references.citation: Eur Respir J. 2005 Aug;26(2):319-38
references.pmid: 16055882
references.citation: Eur Respir J. 2005 Nov;26(5):948-68
references.pmid: 16264058
references.citation: Chest. 2006 Jul;130(1):200-6
references.pmid: 16840402
references.citation: Clin Drug Investig. 2006;26(4):175-83
references.pmid: 17163249
references.citation: Respir Med. 2008 Apr;102(4):593-604
references.pmid: 18083019
references.citation: Eur Respir J. 2008 Apr;31(4):742-50
references.pmid: 18256071
references.citation: J Aerosol Med Pulm Drug Deliv. 2008 Dec;21(4):321-8
references.pmid: 18823257
references.citation: Prim Care Respir J. 2009 Dec;18(4):243-9
references.pmid: 19513494
references.citation: Prim Care Respir J. 2010 Mar;19(1):10-20
references.pmid: 19890594
references.citation: BMJ. 2010;340:c3134
references.pmid: 20581031
references.citation: J Asthma. 2011 Apr;48(3):279-85
references.pmid: 21323613
references.citation: Respir Med. 2011 Jun;105(6):930-8
references.pmid: 21367593
references.citation: BMC Pulm Med. 2011;11:40
references.pmid: 21762500
references.citation: Prim Care Respir J. 2011 Sep;20(3):338-43
references.pmid: 21808941
references.citation: Thorax. 2012 Aug;67(8):718-26
references.pmid: 22544896
references.citation: Thorax. 2012 Aug;67(8):701-8
references.pmid: 22696176